Prognostic value of JAK2V617F mutation in pseudotumor cerebri associated with cerebral venous sinus thrombosis

被引:4
|
作者
Zloto, Ofira [1 ,2 ]
Lubetsky, Aharon [3 ]
Mizrachi, Iris Ben-Bassat [2 ]
Kesler, Anat [1 ]
Quiros, Peter A. [4 ]
Huna-Baron, Ruth [1 ,2 ]
机构
[1] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[2] Sheba Med Ctr, Neuroophthalmol Unit, Tel Hashomer, Israel
[3] Sheba Med Ctr, Thrombosis & Hemostasis Unit, Tel Hashomer, Israel
[4] Univ Calif Los Angeles, Stein Eye Inst, Los Angeles, CA USA
来源
ACTA NEUROLOGICA SCANDINAVICA | 2019年 / 139卷 / 02期
关键词
cerebral venous sinus thrombosis; JAK2V617F mutation; pseudotumor cerebri; JAK2 V617F MUTATION; POLYCYTHEMIA-VERA; THROMBOEMBOLISM; RISK;
D O I
10.1111/ane.13032
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives To examine the clinical characteristics and prognosis of cerebral venous sinus thrombosis (CVST) that presented as pseudotumor cerebri (PTC) patients with JAK2V617F mutation. Methods Medical records of all consecutive patients that presented with PTC and a JAK2V617F mutation who were treated were retrospectively reviewed. Data regarding demographics and ocular presenting symptoms and signs, neurological signs, hematological factors treatment, and prognosis were collected. Results The most common presenting symptoms were headache (5 patients, 83.3%) and visual obscurations (5 patients, 83.3%). CVST of the sagittal sinus and sigmoid sinus were the most common site of thrombus. Platelet count and hemoglobin count were higher than normal during follow-up. There was significant change in the disk edema degree as well as decline in retinal nerve fiber layer (RNFL) thickness (P < 0.001, P < 0.001, Matched pairs). There was no significant change in visual acuity (VA) or mean deviation (MD) during follow-up (P = 0.95, 0.64, respectively, Matched pairs). Conclusions Pseudotumor cerebri resulting from CSVT in our patients with JAK2V617F mutation was frequent in young patients and needed medical and surgical treatment, without improvement in visual functions and in third caused poor visual outcome. Therefore, we believe that a screening test for JAK2V617F mutation should be considered for patients with CVST without known risk factor presenting with PTC, especially when sagittal sinus or sigmoid sinus involvement or thrombocytosis or high hemoglobin are found upon presentation. This might lead to more aggressive management which may improve the visual prognosis of those young patients.
引用
收藏
页码:166 / 171
页数:6
相关论文
共 50 条
  • [41] JAK2V617F mutation is associated with special alleles in essential thrombocythemia
    Hsiao, Hui-Hua
    Liu, Yi-Chang
    Tsai, Hui-Jen
    Lee, Ching-Ping
    Hsu, Jui-Feng
    Lin, Sheng-Fung
    LEUKEMIA & LYMPHOMA, 2011, 52 (03) : 478 - 482
  • [42] Cerebral Venous Sinus Thrombosis as the First Manifestation of JAK2V617F- positive Essential Thrombocythemia
    Chen, Wei-Bi
    Wang, Xian-Ling
    CHINESE MEDICAL JOURNAL, 2018, 131 (06) : 748 - 750
  • [43] Is the JAK2V617F mutation detectable in healthy volunteers?
    Martinaud, Christophe
    Brisou, Patrick
    Mozziconacci, Marie-Joelle
    AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (04) : 287 - 288
  • [44] Monocyte IL-2Rα expression is associated with thrombosis and the JAK2V617F mutation in myeloproliferative neoplasms
    Goette, N. P.
    Lev, P. R.
    Heller, P. G.
    Kornblihtt, L. I.
    Korin, L.
    Molinas, F. C.
    Marta, R. F.
    CYTOKINE, 2010, 51 (01) : 67 - 72
  • [45] Correlative study between the JAK2V617F mutation and thrombosis in patients with myeloproliferative neoplasm
    Li, Z. C.
    Fu, H. J.
    Wang, Z. M.
    Yang, S.
    Xu, H. Z.
    GENETICS AND MOLECULAR RESEARCH, 2016, 15 (03):
  • [46] Percutaneous mesocaval shunt creation for portal thrombosis in a patient with a JAK2V617F mutation
    Farhan, Ahmed
    Liddell, Robert P.
    THROMBOSIS RESEARCH, 2024, 234 : 158 - 161
  • [47] JAK2V617F mutation in patients with arterial thrombosis in the absence of overt myeloproliferative disease
    Dentali, F.
    Squizzato, A.
    Appio, L.
    Brivio, L.
    Ageno, W.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (04) : 722 - 725
  • [48] JAK2V617F mutation in patients with arterial thrombosis in the absence of overt myeloproliferative disease
    Dentali, F.
    Squizzato, A.
    Appio, L.
    Brivio, L.
    Ageno, W.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 740 - 740
  • [49] JAK2V617F mutation and myeloproliferative disorders in splanchnic vein thrombosis: authors' reply
    Westbrook, R. H.
    Mufti, G.
    Heneghan, M. A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (04) : 496 - 497
  • [50] Thrombosis in myeloproliferative disorders: Prevalence, prognostic factors, and the role of leukocytes and JAK2V617F
    Tefferi, Akyalew
    Elliott, Michelle
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2007, 33 (04): : 313 - 320